Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.

@article{Kikuno2007EffectOZ,
  title={Effect of zoledronic acid on metastatic hormone-refractory prostate cancer resistant to taxane, estramustine, carboplatin, and dexamethasone.},
  author={Nobuyuki Kikuno and Shinji Urakami and Shigeru Nakamura and Hiroaki Shiina and Mikio Igawa},
  journal={International journal of urology : official journal of the Japanese Urological Association},
  year={2007},
  volume={14 1},
  pages={82-4}
}
This case report demonstrates the effect of zoledronic acid (ZA) on a patient with bone metastatic hormone-refractory prostate cancer (HRPC) resistant to taxane, estramustine phosphate, carboplatin, and dexamethasone. The pathogenesis, diagnosis, and management of bone metastasis on HRPC are also reviewed.